Move to topTop

TOKYO, JAPAN – June 7, 2022 – Terumo Corporation (TSE: 4543) today announced that it has appointed three associates as the newest "Terumo Fellow". Terumo instituted the Terumo Fellow program to recognize associates who have made outstanding contributions leading to innovation in healthcare, as well as promoting the advancement of technology, research, clinical, and regulatory affairs of the Terumo Group. Terumo Fellows are also nominated for their contribution to transmit Terumo’s core technologies and serve as an inspiration for all associates. Since the establishment of the Terumo Fellow program in 2016, 9 associates have been appointed as a Terumo Fellow. 

Terumo defines "Advancement of healthcare" and "Enhancement of patients' QOL" as its purpose. To realize the advancement of healthcare, Terumo will continue to accelerate activities in the fields of technology, research, clinical and regulatory affairs, to further contribute to healthcare around the world.

Terumo Fellows

Tetsuya Ooyauchi
General Manager, Technology Coordination Office 

Achievements:
・    Development of pen-type insulin injection needles used for diabetes treatment.
・    Development of diabetes-related products, disposable medical devices, ME devices and a wide range of products.

 

Akio Kutsuzawa
General Manager, ME R&D, Cardiac and Vascular Company

Achievements:
・    Realizing commercialization and mass production of the controller of extracorporeal membrane oxygenation (ECMO) system.
・    Engaged in a wide range from elemental technology development to commercialization. Development and commercialization of many ME devices that can be used in combination with disposable medical devices. 

 

Joseph Gulachenski
Senior Director, R&D, MicroVention, Inc. 

Achievements:
・    Led the development of more than 30 medical devices for neurovascular treatment. 
・    Contributed to MicroVention to evolve from a "coil company" to expand beyond cerebral aneurysms to a “neurovascular company” including devices to treat ischemic stroke, carotid artery disease, and neurovascular malformations.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.